1,295 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Is Aegon NV (AEG) a Suitable Stock for Value Investors Now? http://www.zacks.com/stock/news/426167/is-aegon-nv-aeg-a-suitable-stock-for-value-investors-now?cid=CS-ZC-FT-426167 Jun 07, 2019 - Let's see if Aegon NV (AEG) stock is a good choice for value-oriented investors right now from multiple angles.
Novartis Appoints New Pharma Unit Head, Gives Other Updates http://www.zacks.com/stock/news/426279/novartis-appoints-new-pharma-unit-head-gives-other-updates?cid=CS-ZC-FT-426279 Jun 07, 2019 - Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.
Alnylam Completes Rolling NDA Submission to FDA for Givosiran http://www.zacks.com/stock/news/425850/alnylam-completes-rolling-nda-submission-to-fda-for-givosiran?cid=CS-ZC-FT-425850 Jun 06, 2019 - Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
Incyte Begins Phase III Study for Treatment of Duct Cancer http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-ZC-FT-425849 Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Was ASCO Quieter for Big Drug/Biotech Stocks This Year? http://www.zacks.com/stock/news/425444/was-asco-quieter-for-big-drug-biotech-stocks-this-year?cid=CS-ZC-FT-425444 Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Novartis (NVS) Announces Various Data Presentations at ASCO http://www.zacks.com/stock/news/424089/novartis-nvs-announces-various-data-presentations-at-asco?cid=CS-ZC-FT-424089 Jun 03, 2019 - Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
Roche Presents Positive Data on Xolair & Updates From ASCO http://www.zacks.com/stock/news/423876/roche-presents-positive-data-on-xolair-updates-from-asco?cid=CS-ZC-FT-423876 Jun 03, 2019 - Roche (RHHBY) reports positive data from late-stage studies on allergic asthma drug, Xolair, for a new indication, and additional results on Tecentriq and Avastin combo at ASCO.
Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO http://www.zacks.com/stock/news/423909/gilead-presents-data-on-car-t-cell-therapy-candidate-at-asco?cid=CS-ZC-FT-423909 Jun 03, 2019 - Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.
Biogen Reports Interim Phase III Data on Diroximel Fumarate http://www.zacks.com/stock/news/422832/biogen-reports-interim-phase-iii-data-on-diroximel-fumarate?cid=CS-ZC-FT-422832 May 31, 2019 - Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Novartis (NVS) Reports Positive Phase III Data on Asthma Drug http://www.zacks.com/stock/news/422639/novartis-nvs-reports-positive-phase-iii-data-on-asthma-drug?cid=CS-ZC-FT-422639 May 31, 2019 - Novartis' (NVS) investigational, once-daily, fixed dose combination asthma candidate, containing indacaterol acetate and mometasone furoate, meets goals.

Pages: 123456789...130

<<<Page 4>